STAMFORD, Conn.--(BUSINESS WIRE)--(Booth #2539 South Building) – FUJIFILM Medical Systems U.S.A., Inc., will offer the latest version of Synapse RIS, a complete electronic health record (EHR)-certified solution that can be quickly and easily adapted to meet Meaningful Use (MU) Stage II requirements for radiology professionals at the 99th annual meeting of the Radiological Society of North America (RSNA) in Chicago, IL.
“Synapse RIS has integrated EHR into a powerful radiology management tool that can enhance workflow and increase the productivity of radiology practices,” said Jim Morgan, vice president of Medical Informatics, FUJIFILM Medical Systems U.S.A., Inc. “The platform offers the flexibility needed to support additional stages of meaningful use criteria, as well as other government regulations that may be forthcoming.”
Customers can count on continual innovation and comprehensive services provided by Fujifilm. Synapse RIS integrates seamlessly with Synapse PACS and has additional productivity enhancing features for radiologists such as:
- An interactive analytics dashboard that provides a visual snapshot of key performance indicators
- Peer review capabilities directly integrated into the diagnostic process
- Urgent findings for providing closed-loop communications and compliance
- Patient portal capabilities to empower patients, reduce wait times and satisfy meaningful use criteria
Integration with ACR Select allows practices to obtain guidance as to the most appropriate imaging procedure at CPOE and at Point of Schedule. This improves the overall quality of care by ensuring patients get the proper imaging procedure, and the order is based on a structured reason for exam.
The Meaningful Use initiative provides incentive payments to eligible professionals (EPs) who use a certified complete EHR solution in a meaningful way. The American College of Radiologists has projected that 90% of radiologists can qualify for EHR. In the Stage 1 meaningful use regulations, CMS had established a timeline that required providers to progress to Stage 2 criteria after two years under the Stage 1 criteria. This timeline would require Medicare providers who first demonstrated meaningful use in 2011 to meet the Stage 2 criteria in 2014.
To register for a product demonstration at RSNA, please visit http://rsna.fujimed.com. For every product demonstration registered online, Fujiflim will donate $25 to the National Breast Cancer Foundation. For more information about Synapse RIS, please visit: http://www.synapseris.com/
About Fujifilm
FUJIFILM Medical Systems U.S.A., Inc. is a leading provider of diagnostic imaging products and medical informatics solutions to meet the needs of healthcare facilities today and well into the future. From an unrivaled selection of digital x-ray systems, to the Synapse® brand of PACS, RIS and cardiovascular products, to advanced women’s health imaging systems, Fujifilm has products that are ideal for any size imaging environment. The Endoscopy Division of FUJIFILM Medical Systems U.S.A., Inc. supplies high quality, technologically advanced FUJINON brand endoscopes to the medical market. FUJIFILM Medical Systems U.S.A., Inc. is headquartered in Stamford, CT. For more information, please visit www.fujimed.com and www.fujifilmendoscopy.com.
FUJIFILM Holdings Corporation, Tokyo, Japan, brings continuous innovation and leading-edge products to a broad spectrum of industries, including electronic imaging, digital printing equipment, medical systems, life sciences, graphic arts, flat panel display materials, and office products, based on a vast portfolio of digital, optical, fine chemical and thin film coating technologies. The company was among the top 10 companies around the world granted U.S. patents in 2012, and in the year ended March 31, 2013, had global revenues of $26.7 billion*. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visit www.fujifilmholdings.com.
* At an exchange rate of 83 yen to the dollar.